Gossamer Bio Inc - Asset Resilience Ratio
Gossamer Bio Inc (GOSS) has an Asset Resilience Ratio of 82.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Gossamer Bio Inc's Asset Resilience Ratio has changed over time. Check GOSS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Gossamer Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GOSS market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $171.29 Million | 82.03% |
| Total Liquid Assets | $171.29 Million | 82.03% |
Asset Resilience Insights
- Very High Liquidity: Gossamer Bio Inc maintains exceptional liquid asset reserves at 82.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Gossamer Bio Inc Industry Peers by Asset Resilience Ratio
Compare Gossamer Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690 |
Biotechnology | 0.31% |
|
ORUM
KQ:475830 |
Biotechnology | 82.74% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
TG Therapeutics Inc
NASDAQ:TGTX |
Biotechnology | 4.72% |
|
Green Cross Holdings Preference Shares
KO:005257 |
Biotechnology | 0.50% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5 |
Biotechnology | 41.67% |
|
Cybin Inc
NEO:CYBN |
Biotechnology | 0.21% |
Annual Asset Resilience Ratio for Gossamer Bio Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Gossamer Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 78.80% | $248.44 Million | $315.29 Million | -5.94pp |
| 2023-12-31 | 84.74% | $264.32 Million | $311.92 Million | +31.99pp |
| 2022-12-31 | 52.75% | $143.71 Million | $272.45 Million | +11.48pp |
| 2021-12-31 | 41.27% | $141.81 Million | $343.66 Million | +36.34pp |
| 2020-12-31 | 4.93% | $26.57 Million | $539.43 Million | -57.60pp |
| 2019-12-31 | 62.53% | $266.74 Million | $426.60 Million | +10.97pp |
| 2018-12-31 | 51.56% | $123.44 Million | $239.42 Million | -- |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more